Smith & Nephew PLC, known by its stock symbol SNN, is a prominent player in the global healthcare industry. The company's primary business activities involve the development, manufacturing, and distribution of medical devices and implants, as well as providing orthopaedic reconstruction and trauma solutions. Smith & Nephews' operations span across various countries and regions, offering a diverse range of products and services. The company's revenue is primarily generated through the sale of its main products and services, which cater to a broad...
No data available.
No data available.
| S.No. | Ticker | Company | Market Cap | P/E | P/S | Total Debt (Qtr) |
|---|---|---|---|---|---|---|
| 1 | ABT | Abbott Laboratories | 173.80 Bn | 32.73 | 5.47 | 12.94 Bn |
| 2 | SYK | Stryker Corp | 141.15 Bn | 43.48 | 5.62 | 15.86 Bn |
| 3 | MDT | Medtronic plc | 123.47 Bn | 25.92 | 3.55 | 29.10 Bn |
| 4 | BSX | Boston Scientific Corp | 112.80 Bn | 38.92 | 5.62 | 11.44 Bn |
| 5 | EW | Edwards Lifesciences Corp | 45.66 Bn | 33.38 | 7.76 | 0.70 Bn |
| 6 | DXCM | Dexcom Inc | 27.52 Bn | 32.91 | 5.90 | 1.34 Bn |
| 7 | STE | STERIS plc | 24.13 Bn | 34.08 | 4.14 | 2.05 Bn |
| 8 | PODD | Insulet Corp | 17.33 Bn | 70.38 | 6.87 | 1.01 Bn |
| Current Valuation | Value | Ind Avg | Percentile |
|---|---|---|---|
| EV to Assets EV to Assets | 1.59 | 2.13 | |
| EV to Cash from Ops. EV/CFO | 18.25 | 2.75 | |
| EV to Debt EV to Debt | 4.92 | 17.25 | |
| EV to EBIT EV/EBIT | 20.22 | 2.89 | |
| EV to EBITDA EV/EBITDA | 13.09 | 4.53 | |
| EV to Free Cash Flow [EV/FCF] EV/FCF | 29.09 | 29.36 | |
| EV to Market Cap EV to Market Cap | 1.09 | 25.09 | |
| EV to Revenue EV/Rev | 3.46 | 32.80 | |
| Price to Book Value [P/B] P/B | 3.20 | 4.73 | |
| Price to Earnings [P/E] P/E | 23.50 | -2.04 |
| Dividend Metrics | Value | Ind Avg | Percentile |
|---|---|---|---|
| Dividend Coverage Ratio Dividend Coverage Ratio | 1.26 | 40.22 | |
| Dividend Payout Ratio % Div Payout % (Qtr) | 66.70 | 1.59 | |
| Dividend per Basic Share Div per Share (Qtr) | 0.75 | 0.10 | |
| FCF Dividend Payout Ratio % FCF Dividend Payout Ratio % | 54.31 | -0.37 | |
| Interest Coverage Int. cover (Qtr) | 4.43 | 196.93 |
| Growth Metrics | Value | Ind Avg | Percentile |
|---|---|---|---|
| Capex Growth (1y) % Capex 1y % (Qtr) | 10.77 | -152.08 | |
| Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) | 19.01 | 8,476.58 | |
| Dividend Growth (1y) % Dividend Growth (1y) % | 0.00 | -0.44 | |
| EBIAT Growth (1y) % EBIAT 1y % (Qtr) | 39.00 | -792.16 | |
| EBITDA Growth (1y) % EBITDA 1y % (Qtr) | 17.51 | 3.79 | |
| EBIT Growth (1y) % EBIT 1y % (Qtr) | 52.37 | -301.80 | |
| EBT Growth (1y) % EBT 1y % (Qtr) | 71.72 | -121.44 | |
| EPS Growth (1y) % EPS 1y % (Qtr) | 60.57 | -87.51 | |
| FCF Growth (1y) % FCF 1y % (Qtr) | 234.81 | 10.43 | |
| Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) | 5.94 | 38.21 |
| Liquidity Ratios | Value | Ind Avg | Percentile |
|---|---|---|---|
| Asset Utilization Ratio Asset Util Ratio (Qtr) | 0.54 | 0.55 | |
| Cash Payout Ratio Cash Payout Ratio | 0.24 | 0.02 | |
| Cash Ratio Cash Ratio (Qtr) | 0.44 | 1.80 | |
| Current Ratio Curr Ratio (Qtr) | 3.00 | 4.18 | |
| Debt to Equity Ratio Debt/Equity (Qtr) | 0.62 | 1.20 | |
| Interest Cover Ratio Int Coverage (Qtr) | 4.43 | 196.93 | |
| Times Interest Earned Times Interest Earned (Qtr) | 4.43 | 196.93 |
| Profitability | Value | Ind Avg | Percentile |
|---|---|---|---|
| EBITDA Margin % EBITDA Margin % (Qtr) | 22.20 | -2,396.63 | |
| EBIT Margin % EBIT Margin % (Qtr) | 11.07 | -2,478.60 | |
| EBT Margin % EBT Margin % (Qtr) | 8.57 | -2,690.42 | |
| Gross Margin % Gross Margin % (Qtr) | 69.60 | 30.80 | |
| Net Profit Margin % Net Margin % (Qtr) | 7.10 | -2,821.53 |